1 |
Kim IS, Gu A, Lee JS. The role of S100A8 and S100A9 in differentiation of human eosinophilic leukemia cells, EoL-1. Biomed Sci Lett. 2017. 23: 44-47.
DOI
|
2 |
Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015. 126: 1069-1077.
DOI
|
3 |
Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008. 143: 707-715.
DOI
|
4 |
Nishioka C, Ikezoe T, Yang J, Yokoyama A. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia. 2010. 24: 1631-1640.
DOI
|
5 |
Qu SQ, Qin TJ, Xu ZF, Zhang Y, Ai XF, Li B, Zhang HL, Fang LW, Pan LJ, Hu NB, Xiao ZJ. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 2016. 7: 33229-33236.
|
6 |
Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017. 129: 704-714.
DOI
|
7 |
Si J, Yu X, Zhang Y, DeWille JW. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer. 2010. 9: 92.
DOI
|
8 |
Yeh HH, Tseng YF, Hsu YC, Lan SH, Wu SY, Raghavaraju G, Cheng DE, Lee YR, Chang TY, Chow NH, Hung WC, Liu HS. Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity. BMC Cancer. 2015. 15: 172.
DOI
|
9 |
Antoniu SA. Novel therapies for hypereosinophilic syndromes. Neth J Med. 2010. 68: 304-310.
|